Crystal structure-based virtual screening for fragment-like ligands of the human histamine H 1 receptor

Journal of Medicinal Chemistry

Volumn 54, Issue 23, 2011, Pages 8195-8206

  De Graaf, Chris ^a   Kooistra, Albert J ^a   Vischer, Henry F ^a   Katritch, Vsevolod ^b   Kuijer, Martien ^a   Shiroishi, Mitsunori ^c,d   Iwata, So ^c,e,f,g   Shimamura, Tatsuro ^c,g   Stevens, Raymond C ^b   De Esch, Iwan J P ^a   Leurs, Rob ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f DIAMOND LIGHT SOURCE LTD   (United Kingdom)

^g KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; BENZOAMIDAZOTRIAZOLE; BENZOFUROPYRIMIDINE; DIHYDROBENZOIMIDAZOTRIAZINE; DOXEPIN; G PROTEIN COUPLED RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; MEPYRAMINE; NONCYCLIC AMINE DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLOPYRIMIDINE DERIVATIVE; PYROLOPYRIDINE; TETRAZOLOQUINAZOLINE; TIENOPYRIMIDINE; TRIAZOLOINDAZOLE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; ATOM; BINDING AFFINITY; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EMBRYO; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOLECULAR WEIGHT; PROTEIN LIGAND INTERACTION FINGERPRINT SCORING METHOD; PROTEIN STRUCTURE;

DATABASES, FACTUAL; HEK293 CELLS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RADIOLIGAND ASSAY; RECEPTORS, HISTAMINE H1;

EID: 82555187387     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2011589     Document Type: Article

References (79)

1. Lagerstrom, M. C.; Schioth, H. B. Structural diversity of G protein-coupled receptors and significance for drug discovery Nat. Rev. Drug Discovery 2008, 7, 339-357
2. Rosenbaum, D. M.; Rasmussen, S. G.; Kobilka, B. K. The structure and function of G protein-coupled receptors Nature 2009, 459, 356-363
3. Topiol, S.; Sabio, M. X-ray structure breakthroughs in the GPCR transmembrane region Biochem. Pharmacol. 2009, 78, 11-20
4. Congreve, M.; Langmead, C. J.; Mason, J. S.; Marshall, F. H. Progress in structure based drug design for G protein-coupled receptors J. Med. Chem. 2011, 54, 4283-4311
5. de Graaf, C.; Rognan, D. Customizing G protein-coupled receptor models for structure-based virtual screening Curr. Pharm. Des. 2009, 15, 4026-4048
6. 1-Antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects Clin. Exp. Allergy 2002, 32, 489-498
7. Shimamura, T.; Shiroishi, M.; Weyand, S.; Tsujimoto, H.; Winter, G.; Katritch, V.; Abagyan, R.; Cherezov, V.; Liu, W.; Han, G. W.; Kobayashi, T.; Stevens, R. C.; Iwata, S. Structure of the human histamine H1 receptor complex with doxepin Nature 2011, 475, 65-70
8. Varady, J.; Wu, X.; Fang, X.; Min, J.; Hu, Z.; Levant, B.; Wang, S. Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach J. Med. Chem. 2003, 46, 4377-4392
9. Clark, D. E.; Higgs, C.; Wren, S. P.; Dyke, H. J.; Wong, M.; Norman, D.; Lockey, P. M.; Roach, A. G. A virtual screening approach to finding novel and potent antagonists at the melanin-concentrating hormone 1 receptor J. Med. Chem. 2004, 47, 3962-3971
10. Evers, A.; Klebe, G. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model J. Med. Chem. 2004, 47, 5381-5392
11. Edwards, B. S.; Bologa, C.; Young, S. M.; Balakin, K. V.; Prossnitz, E. R.; Savchuck, N. P.; Sklar, L. A.; Oprea, T. I. Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists Mol. Pharmacol. 2005, 68, 1301-1310
12. Evers, A.; Klabunde, T. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor J. Med. Chem. 2005, 48, 1088-1097
13. Salo, O. M.; Raitio, K. H.; Savinainen, J. R.; Nevalainen, T.; Lahtela-Kakkonen, M.; Laitinen, J. T.; Jarvinen, T.; Poso, A. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor J. Med. Chem. 2005, 48, 7166-7171
14. Kellenberger, E.; Springael, J. Y.; Parmentier, M.; Hachet-Haas, M.; Galzi, J. L.; Rognan, D. Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening J. Med. Chem. 2007, 50, 1294-1303
15. Cavasotto, C. N.; Orry, A. J.; Murgolo, N. J.; Czarniecki, M. F.; Kocsi, S. A.; Hawes, B. E.; O'Neill, K. A.; Hine, H.; Burton, M. S.; Voigt, J. H.; Abagyan, R. A.; Bayne, M. L.; Monsma, F. J., Jr. Discovery of novel chemotypes to a G protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening J. Med. Chem. 2008, 51, 581-588
16. Engel, S.; Skoumbourdis, A. P.; Childress, J.; Neumann, S.; Deschamps, J. R.; Thomas, C. J.; Colson, A. O.; Costanzi, S.; Gershengorn, M. C. A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists J. Am. Chem. Soc. 2008, 130, 5115-5123
17. Kiss, R.; Kiss, B.; Konczol, A.; Szalai, F.; Jelinek, I.; Laszlo, V.; Noszal, B.; Falus, A.; Keseru, G. M. Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening J. Med. Chem. 2008, 51, 3145-3153
18. Tikhonova, I. G.; Sum, C. S.; Neumann, S.; Engel, S.; Raaka, B. M.; Costanzi, S.; Gershengorn, M. C. Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening J. Med. Chem. 2008, 51, 625-633
19. Klabunde, T.; Giegerich, C.; Evers, A. Sequence-derived three-dimensional pharmacophore models for G protein-coupled receptors and their application in virtual screening J. Med. Chem. 2009, 52, 2923-2932
20. Salon, J. A.; Lodowski, D. T.; Palczewski, K. The significance of G protein-coupled receptor crystallography for drug discovery Pharmacol. Rev. 2011, 63, 901-937
21. Kolb, P.; Rosenbaum, D. M.; Irwin, J. J.; Fung, J. J.; Kobilka, B. K.; Shoichet, B. K. Structure-based discovery of beta2-adrenergic receptor ligands Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 6843-6848
22. Carlsson, J.; Yoo, L.; Gao, Z. G.; Irwin, J. J.; Shoichet, B. K.; Jacobson, K. A. Structure-based discovery of A2A adenosine receptor ligands J. Med. Chem. 2010, 53, 3748-3755
23. Katritch, V.; Jaakola, V. P.; Lane, J. R.; Lin, J.; Ijzerman, A. P.; Yeager, M.; Kufareva, I.; Stevens, R. C.; Abagyan, R. Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists J. Med. Chem. 2010, 53, 1799-1809
24. Sabio, M.; Jones, K.; Topiol, S. Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds Bioorg. Med. Chem. Lett. 2008, 18, 5391-5395
25. de Kloe, G. E.; Bailey, D.; Leurs, R.; de Esch, I. J. Transforming fragments into candidates: small becomes big in medicinal chemistry Drug Discovery Today 2009, 14, 630-646
26. Rognan, D. Fragment-based approaches and computer-aided drug discovery Top. Curr. Chem. 2011, 1-22
27. de Graaf, C.; Rognan, D. Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor J. Med. Chem. 2008, 51, 4978-4985
28. Korb, O.; Stützle, T.; Exner, T. E. An ant colony optimization approach to flexible protein-ligand docking Swarm Intell. 2007, 1, 115-134
29. Overington, J. ChEMBL, an interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI). Interview by Wendy A. Warr J. Comput.-Aided Mol. Des. 2009, 23, 195-198
30. Bakker, R. A.; Nicholas, M. W.; Smith, T. T.; Burstein, E. S.; Hacksell, U.; Timmerman, H.; Leurs, R.; Brann, M. R.; Weiner, D. M. In vitro pharmacology of clinically used central nervous system-active drugs as inverse H(1) receptor agonists J. Pharmacol. Exp. Ther. 2007, 322, 172-179
31. Korb, O.; Stützle, T.; Exner, T. E. Empirical scoring functions for advanced protein-ligand docking with PLANTS J. Chem. Inf. Model. 2009, 49, 84-96
32. Marcou, G.; Rognan, D. Optimizing fragment and scaffold docking by use of molecular interaction fingerprints J. Chem. Inf. Model. 2007, 47, 195-207
33. Ferrara, P.; Gohlke, H.; Price, D. J.; Klebe, G.; Brooks, C. L., 3rd. Assessing scoring functions for protein-ligand interactions J. Med. Chem. 2004, 47, 3032-3047
34. Jain, A. N.; Nicholls, A. Recommendations for evaluation of computational methods J. Comput.-Aided Mol. Des. 2008, 22, 133-139
35. Irwin, J. J.; Shoichet, B. K. ZINC-a free database of commercially available compounds for virtual screening J. Chem. Inf. Model. 2005, 45, 177-182
36. Verheij, M. H.; de Graaf, C.; de Kloe, G. E.; Nijmeijer, S.; Vischer, H. F.; Smits, R. A.; Zuiderveld, O. P.; Hulscher, S.; Silvestri, L.; Thompson, A. J.; van Muijlwijk-Koezen, J. E.; Lummis, S. C.; Leurs, R.; de Esch, I. J. Fragment library screening reveals remarkable similarities between the G protein-coupled receptor histamine H(4) and the ion channel serotonin 5-HT(3A) Bioorg. Med. Chem. Lett. 2011, 5460-5464
37. Siegal, G.; Ab, E.; Schultz, J. Integration of fragment screening and library design Drug Discovery Today 2007, 12, 1032-1039
38. Bruysters, M.; Pertz, H. H.; Teunissen, A.; Bakker, R. A.; Gillard, M.; Chatelain, P.; Schunack, W.; Timmerman, H.; Leurs, R. Mutational analysis of the histamine H1-receptor binding pocket of histaprodifens Eur. J. Pharmacol. 2004, 487, 55-63
39. Wawer, M.; Bajorath, J. Similarity-potency trees: a method to search for SAR information in compound data sets and derive SAR rules J. Chem. Inf. Model. 2010, 50, 1395-1409
40. Becker, O. M.; Dhanoa, D. S.; Marantz, Y.; Chen, D.; Shacham, S.; Cheruku, S.; Heifetz, A.; Mohanty, P.; Fichman, M.; Sharadendu, A.; Nudelman, R.; Kauffman, M.; Noiman, S. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression J. Med. Chem. 2006, 49, 3116-3135
41. Holst, B.; Nygaard, R.; Valentin-Hansen, L.; Bach, A.; Engelstoft, M. S.; Petersen, P. S.; Frimurer, T. M.; Schwartz, T. W. A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane receptors J. Biol. Chem. 2010, 285, 3973-3985
42. Jongejan, A.; Bruysters, M.; Ballesteros, J. A.; Haaksma, E.; Bakker, R. A.; Pardo, L.; Leurs, R. Linking agonist binding to histamine H1 receptor activation Nat. Chem. Biol. 2005, 1, 98-103
43. Katritch, V.; Abagyan, R. GPCR agonist binding revealed by modeling and crystallography Trends Pharmacol. Sci. 2011, 32, 637-643
44. Rasmussen, S. G.; Choi, H. J.; Fung, J. J.; Pardon, E.; Casarosa, P.; Chae, P. S.; Devree, B. T.; Rosenbaum, D. M.; Thian, F. S.; Kobilka, T. S.; Schnapp, A.; Konetzki, I.; Sunahara, R. K.; Gellman, S. H.; Pautsch, A.; Steyaert, J.; Weis, W. I.; Kobilka, B. K. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor Nature 2011, 469, 175-180
45. Rognan, D. Docking Methods for Virtual Screening: Principles and Recent Advances. In Virtual Screening; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2011; pp 153-176.
46. Carlsson, J.; Coleman, R. G.; Setola, V.; Irwin, J. J.; Fan, H.; Schlessinger, A.; Sali, A.; Roth, B. L.; Shoichet, B. K. Ligand discovery from a dopamine D3 receptor homology model and crystal structure Nat. Chem. Biol. 2011, 7, 769-778
47. Wieland, K.; Laak, A. M.; Smit, M. J.; Kuhne, R.; Timmerman, H.; Leurs, R. Mutational analysis of the antagonist-binding site of the histamine H(1) receptor J. Biol. Chem. 1999, 274, 29994-30000
48. Ohta, K.; Hayashi, H.; Mizuguchi, H.; Kagamiyama, H.; Fujimoto, K.; Fukui, H. Site-directed mutagenesis of the histamine H1 receptor: roles of aspartic acid107, asparagine198 and threonine194 Biochem. Biophys. Res. Commun. 1994, 203, 1096-1101
49. Kufareva, I.; Rueda, M.; Katritch, V.; Stevens, R. C.; Abagyan, R. Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment Structure 2011, 19, 1108-1126
50. O'Boyle, N. M.; Liebeschuetz, J. W.; Cole, J. C. Testing assumptions and hypotheses for rescoring success in protein-ligand docking J. Chem. Inf. Model. 2009, 49, 1871-1878
51. Kellenberger, E.; Foata, N.; Rognan, D. Ranking targets in structure-based virtual screening of three-dimensional protein libraries: methods and problems J. Chem. Inf. Model. 2008, 48, 1014-1025
52. Knox, A. J.; Meegan, M. J.; Sobolev, V.; Frost, D.; Zisterer, D. M.; Williams, D. C.; Lloyd, D. G. Target specific virtual screening: optimization of an estrogen receptor screening platform J. Med. Chem. 2007, 50, 5301-5310
53. Rogers, D.; Hahn, M. Extended-connectivity fingerprints J. Chem. Inf. Model. 2010, 50, 742-754
54. Grant, J. A.; Gallardo, M. A.; Pickup, B. T. A fast method of molecular shape comparison: a simple application of a Gaussian description of molecular shape J. Comput. Chem. 1996, 17, 1653-1666
55. Steffen, A.; Kogej, T.; Tyrchan, C.; Engkvist, O. Comparison of molecular fingerprint methods on the basis of biological profile data J. Chem. Inf. Model. 2009, 49, 338-347
56. Fan, Y.; Lai, M. H.; Sullivan, K.; Popiolek, M.; Andree, T. H.; Dollings, P.; Pausch, M. H. The identification of neurotensin NTS1 receptor partial agonists through a ligand-based virtual screening approach Bioorg. Med. Chem. Lett. 2008, 18, 5789-5791
57. Gillespie, R. J.; Cliffe, I. A.; Dawson, C. E.; Dourish, C. T.; Gaur, S.; Jordan, A. M.; Knight, A. R.; Lerpiniere, J.; Misra, A.; Pratt, R. M.; Roffey, J.; Stratton, G. C.; Upton, R.; Weiss, S. M.; Williamson, D. S. Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4- d ]pyrimidines, pyrrolo[2,3- d ]pyrimidines and 6-arylpurines Bioorg. Med. Chem. Lett. 2008, 18, 2924-2929
58. Miller, D. C.; Klute, W.; Calabrese, A.; Brown, A. D. Optimising metabolic stability in lipophilic chemical space: the identification of a metabolically stable pyrazolopyrimidine CRF-1 receptor antagonist Bioorg. Med. Chem. Lett. 2009, 19, 6144-6147
59. Shi, L.; Javitch, J. A. The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop Annu. Rev. Pharmacol. Toxicol. 2002, 42, 437-467
60. Surgand, J. S.; Rodrigo, J.; Kellenberger, E.; Rognan, D. A chemogenomic analysis of the transmembrane binding cavity of human G protein-coupled receptors Proteins 2006, 62, 509-538
61. Venhorst, J.; Nunez, S.; Terpstra, J. W.; Kruse, C. G. Assessment of scaffold hopping efficiency by use of molecular interaction fingerprints J. Med. Chem. 2008, 51, 3222-3229
62. Xu, J. A new approach to finding natural chemical structure classes J. Med. Chem. 2002, 45, 5311-5320
63. Celanire, S.; Wijtmans, M.; Talaga, P.; Leurs, R.; de Esch, I. J. Keynote review: histamine H3 receptor antagonists reach out for the clinic Drug Discovery Today 2005, 10, 1613-1627
64. Westly, E. Nothing to sneeze at Nat. Med. 2010, 16, 1063-1065
65. Lim, H. D.; de Graaf, C.; Jiang, W.; Sadek, P.; McGovern, P. M.; Istyastono, E. P.; Bakker, R. A.; de Esch, I. J.; Thurmond, R. L.; Leurs, R. Molecular determinants of ligand binding to H4R species variants Mol. Pharmacol. 2010, 77, 734-743
66. Gillard, M.; Van Der Perren, C.; Moguilevsky, N.; Massingham, R.; Chatelain, P. Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194) Mol. Pharmacol. 2002, 61, 391-399
67. Ballesteros, J. A.; Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors Methods Neurosci. 1995, 25, 366-428
68. Wu, C. H.; Apweiler, R.; Bairoch, A.; Natale, D. A.; Barker, W. C.; Boeckmann, B.; Ferro, S.; Gasteiger, E.; Huang, H.; Lopez, R.; Magrane, M.; Martin, M. J.; Mazumder, R.; O'Donovan, C.; Redaschi, N.; Suzek, B. The Universal Protein Resource (UniProt): an expanding universe of protein information Nucleic Acids Res. 2006, 34, D187-D191
69. Bioinfo 11.1. http://bioinfo-pharma.u-strasbg.fr/bioinfo (accessed June 6, 2011).
70. Calculator, version 5.1.4; ChemAxon: Budapest, Hungary.
71. Corina, version 3.46; Molecular Networks GmbH: Erlangen, Germany.
72. FILTER, version 2.1.1; OpenEye Scientific Software: Santa Fe, NM.
73. MoKa, version 1.1.0; Molecular Discovery Ltd.: Pinner, Middlesex, U.K.
74. Pipeline Pilot, version 6.1.5; Accelrys: San Diego, CA.
75. Omega, version 2.3.2; OpenEye Scientific Software: Santa Fe, NM.
76. ROCS, version 2.3.1; OpenEye Scientific Software: Santa Fe, NM.
77. MOE, version 2010.10; Chemical Computing Group, Inc.: Montreal, Canada.
78. Fukui, H.; Fujimoto, K.; Mizuguchi, H.; Sakamoto, K.; Horio, Y.; Takai, S.; Yamada, K.; Ito, S. Molecular cloning of the human histamine H1 receptor gene Biochem. Biophys. Res. Commun. 1994, 201, 894-901
79. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108